top of page

The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

🔬✨ It's time for a review! Felix Poppelaars, Bernardo Faria, Wilhelm Schwaeble, and Mohamed R Daha have come together to discuss the role of the complement system in IgA nephropathy (IgAN), a leading cause of chronic kidney disease and kidney failure.

🔍IgAN currently lacks disease-specific treatment options, but that might change soon! Novel therapeutic approaches, including complement-targeting therapies, are being assessed in clinical trials. The development of these strategies is based on a deeper understanding of the lectin and alternative pathways of complement in IgAN's pathophysiology.

🌟 In a recent phase 2 trial, a blocking antibody against MASP-2 (a crucial enzyme of the lectin pathway) showed potential benefits for IgAN patients. A phase 3 study is now underway, and this MASP-2 inhibitor could mark the beginning of a new era in complement therapeutics.

👩‍⚕️ As these therapies advance, it's crucial for physicians to understand the biology of complement, its pathogenic role in IgAN, and complement-targeted therapies. This review aims to provide an overview of the role of complement in IgAN and explore new mechanisms of complement activation and potential complement inhibitors as treatment options.

🙌 Hats off to Felix Poppelaars, Bernardo Faria, Wilhelm Schwaeble, and Mohamed R Daha for their comprehensive review! Stay tuned for more developments in the world of complement-targeted therapies! #IgANephropathy #chronickidneydisease #complementtherapeutics #review

Find the full article here

4 views0 comments

Recent Posts

See All


bottom of page